Guatemala vs Luxembourg: Access to anti-retroviral drugs, male
Guatemala
82.0%
in 2024
Luxembourg
83.0%
in 2024
Guatemala rank
42nd
Luxembourg rank
40th
Access to anti-retroviral drugs, male over time
- Guatemala
- Luxembourg
How they compare
Luxembourg currently reports 83.0% against 82.0% in Guatemala, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Luxembourg ahead.
Guatemala ranks 42nd and Luxembourg ranks 40th of 141 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guatemala | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19.8% | 45.0% | 25.2% | Luxembourg |
| 2010s | 57.3% | 63.6% | 6.3% | Luxembourg |
| 2020s | 77.8% | 78.8% | 1.0% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Guatemala or Luxembourg?
- Luxembourg, at 83.0% against 82.0% in Guatemala as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Guatemala and Luxembourg?
- 1.0%, with Luxembourg ahead.
- How many years of comparable data are there for Guatemala and Luxembourg?
- 25 years are reported by both, from 2000 to 2024.
- How do Guatemala and Luxembourg rank globally for access to anti-retroviral drugs, male?
- Guatemala ranks 42nd and Luxembourg ranks 40th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.